Hashimoto, Kenji http://orcid.org/0000-0002-8892-0439
Funding for this research was provided by:
MEXT | Japan Society for the Promotion of Science (21H02846, 21H00184, 21H05612)
Article History
Received: 24 January 2022
Revised: 11 April 2022
Accepted: 13 April 2022
First Online: 27 April 2022
Competing interests
: Dr. Hashimoto is the inventor of filed patent applications on “The use of <i>R</i>-ketamine in the treatment of psychiatric diseases”, “(<i>S</i>)-norketamine and salt thereof as pharmaceutical”, “<i>R</i>-ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition function disorder”, “Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases”, “<i>R</i>-ketamine and its derivatives as a preventive or therapeutic agent for a neurodevelopmental disorder”, and “TGF-β1 in the treatment of depression” by the Chiba University. Dr. Hashimoto also declares that he has received research support and consultant from Dainippon Sumitomo, Otsuka, Taisho, Murakami Farm, and Perception Neuroscience.